A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality.


Journal

Experimental and clinical psychopharmacology
ISSN: 1936-2293
Titre abrégé: Exp Clin Psychopharmacol
Pays: United States
ID NLM: 9419066

Informations de publication

Date de publication:
05 Oct 2023
Historique:
medline: 5 10 2023
pubmed: 5 10 2023
entrez: 5 10 2023
Statut: aheadofprint

Résumé

The present study sought to determine the effects of cannabinol (CBN) alone and in combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized, placebo-controlled study conducted between May and November 2022. Participants were randomized to receive either (a) placebo, (b) 20 mg CBN, (c) 20 mg CBN + 10 mg CBD, (d) 20 mg CBN + 20 mg CBD, or (e) 20 mg CBN + 100 mg CBD for seven consecutive nights. Participants were 18-55 years of age who self-rated sleep quality as "very poor" or "poor." The primary endpoint was sleep quality, while secondary endpoints included sleep onset latency, number of awakenings, wake after sleep onset (WASO), overall sleep disturbance, and daytime fatigue. In a modified intent-to-treat analyses (

Identifiants

pubmed: 37796540
pii: 2024-14146-001
doi: 10.1037/pha0000682
doi:

Banques de données

ClinicalTrials.gov
['NCT05839964']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Canopy Growth Corporation

Auteurs

Marcel O Bonn-Miller (MO)

Canopy Growth Corporation.

Matthew T Feldner (MT)

Canopy Growth Corporation.

Teah M Bynion (TM)

Canopy Growth Corporation.

Graham M L Eglit (GML)

Canopy Growth Corporation.

Megan Brunstetter (M)

Canopy Growth Corporation.

Maja Kalaba (M)

Canopy Growth Corporation.

Ivori Zvorsky (I)

Canopy Growth Corporation.

Erica N Peters (EN)

Canopy Growth Corporation.

Mike Hennesy (M)

Wana Brands.

Classifications MeSH